The U.S. Food and Drug Administration (FDA) has approved the first generic version of the Pharmaceutical company Roche’s flu drug Xofluza (baloxavir marboxil). The FDA approval for Roche’s flu drug allows healthcare providers to prescribe generic baloxavir marboxil tablets to treat acute, uncomplicated influenza for patients aged five years and older.
Xofluza drug is manufactured by Norwich Pharmaceuticals, which has been marketed in the U.S. by Genentech since its original FDA approval in 2018.
Xofluza’s approval by the FDA is a significant step in expanding access to influenza treatment in the United States before the upcoming flu season.
“Today’s approval marks a meaningful milestone for the treatment of influenza,” said Iilun Murphy, M.D., Director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research.
What Makes Roche’s Generic Drug Xofluza Different?
The generic version of Roche’s Xofluza contains baloxavir marboxil, an antiviral medicine that works by stopping the influenza virus from multiplying inside the body. Like the branded medicine, it is most effective when started within the first 48 hours after flu symptoms begin.
One of the biggest advantages of Roche’s generic drug Xofluza is its single-dose design. Unlike some antiviral medicines that require treatment over several days, Roche’s single-dose oral antiviral medication is taken only once.
This simpler dosing schedule may improve treatment adherence, especially for children, older adults, and patients who may struggle to complete multi-day medication courses.
Who Can Receive the Generic Version of Roche’s Flu Drug?
The generic version of Roche’s Xofluza is safe to receive for:
- Adults and children aged five years and older.
- Otherwise healthy patients with uncomplicated influenza.
- Individuals at high risk of developing influenza-related complications.
- Patients requiring influenza prevention after exposure to an infected person.
However, Roche’s new influenza medicine should not be used by people with a known allergy to baloxavir marboxil or any of its ingredients.
The FDA also notes that healthcare providers should carefully review prescribing information because treatment-emergent resistance has been observed in certain younger patients.
Common side effects of flu drug Xofluza include:
- Diarrhea
- Bronchitis
- Nausea
- Sinusitis
- Headache
Roche’s Single-dose Flu Drug Xofluza Beyond the US
The FDA approval for Roche’s flu drug will help the pharma company to expand access to influenza treatment beyond the United States.
Earlier this year, Roche announced a generic Xofluza licensing agreement with the Medicines Patent Pool (MPP), a United Nations-backed public health organization. The voluntary licensing agreement allows qualified generic manufacturers to develop, produce, and supply baloxavir marboxil across 129 low- and middle-income countries.
The initiative aims to improve access to antiviral medicines while strengthening global preparedness for future influenza outbreaks and potential pandemics.
According to Roche, the agreement supports equitable access to treatment while helping build manufacturing capacity before future public health emergencies.
Significance of The FDA Approval for Roche’s Flu Drug
The FDA approval for Roche’s flu drug could have a meaningful impact on both patients and the healthcare system. Generic medicines account for approximately nine out of every 10 prescriptions filled in the United States, according to the FDA, making them an important tool for reducing healthcare costs and improving access.
As seasonal influenza continues to cause millions of illnesses each year, by introducing competition into the market, the FDA approval for Roche’s flu drug may help lower treatment costs over time while ensuring patients have access to a convenient, single-dose antiviral option.
